How did WHO, the European Commission, the ECDC (European Centre for Disease Prevention and Control) and the European Medicines Agency learn about oseltamivir resistance in influenza viruses?
On 25 January 2008, the Norwegian authorities officially notified their EU partners and WHO, via the International Health Regulations (IHR) mechanism and the European Early Warning and Response System (EWRS) about a high rate of resistance to an antiviral drug, oseltamivir (Tamiflu©) in seasonal influenza A(H1N1) viruses. Of 16 virus isolates tested, 12 (75%) were resistant to oseltamivir. All the viruses were collected from patients earlier in the influenza season in November and December 2007 in Norway. Testing had been undertaken by National Institute of Public Health, the European Surveillance Network for Vigilance Against Viral Resistance (VIRGIL), the WHO Collaborating Center (CC) at the MRC National Institute for Medical Research in London and the European Influenza Surveillance Scheme (EISS).
Related Questions
- How did WHO, the European Commission, the ECDC (European Centre for Disease Prevention and Control) and the European Medicines Agency learn about oseltamivir resistance in influenza viruses?
- A recent Centers for Disease Control and Prevention (CDC) study reported bisphenol A (BPA) in a high percentage of people; is this a concern?
- How can I learn more about the Centers for Disease Control and Prevention (CDC)?
